Darolutamide is the preferred choice for this patient with Alzheimer's disease and cardiovascular concerns
In an elderly man with prostate cancer and Alzheimer's disease requiring an androgen receptor pathway inhibitor, darolutamide should be selected over enzalutamide due to its superior cognitive and cardiovascular safety profile.
Cognitive Safety: The Critical Differentiator
The most compelling evidence comes from the ODENZA trial 1, a 2024 head-to-head randomized crossover study that directly compared darolutamide and enzalutamide in 249 patients with metastatic castration-resistant prostate cancer. This study demonstrated:
- Darolutamide showed a clinically meaningful benefit in episodic memory with improved acquisition of new information (effect size = 0.5) and recall after brief delay (effect size = 0.3)
- Patients reported significantly less fatigue with darolutamide (2.7) versus enzalutamide (3.3) on the Brief Fatigue Inventory
This cognitive advantage is particularly critical for your patient with pre-existing Alzheimer's disease. The 2025 ASCO guidelines 2 explicitly warn that "ADT can reduce executive functioning and accelerate cognitive decline associated with aging," making the choice of ARPI crucial in this vulnerable population.
The NCCN guidelines 3 document that enzalutamide carries a 5% risk of mental impairment disorders versus 2% with placebo in the PROSPER trial, while darolutamide demonstrated no such signal in ARAMIS.
Cardiovascular Safety Profile
For cardiovascular safety, the evidence strongly favors darolutamide:
Falls Risk
A 2026 meta-analysis of 11 RCTs 4 found:
- Enzalutamide: RR 2.55 for all-grade falls (highest risk among ARPIs)
- Darolutamide: RR 1.25 (not statistically significant; 97.5% CI 0.87-1.79)
Hypertension Risk
A 2026 systematic review 5 demonstrated:
- Enzalutamide monotherapy: RR 2.20 for all-grade hypertension
- Darolutamide: Relatively favorable cardiovascular safety profile with lower hypertension risk
Major Adverse Cardiovascular Events
The FDA label 6 and NCCN guidelines 3 report enzalutamide carries a 5% risk of major adverse cardiovascular events versus 3% with placebo in PROSPER.
Number Needed to Harm Analysis
A 2026 NNH analysis 7 comparing ARPIs in nmCRPC found darolutamide had higher NNH (lower risk) than enzalutamide for:
- Cognitive impairment: ≥250 vs 33.3
- Fatigue: 29.4 vs 5.3
- Hypertension: 71.4 vs 14.3
- Falls: Negative (no excess risk) vs 14.3
Efficacy Considerations
Both agents are Category 1, preferred options per NCCN guidelines 3. A 2026 real-world study 8 of 198 patients found comparable PSA responses and progression outcomes between enzalutamide and darolutamide, confirming equivalent efficacy.
Practical Implementation
Darolutamide dosing: 600 mg (two 300 mg tablets) twice daily with food 9
Key monitoring for this patient:
- Baseline and periodic cognitive assessment (given Alzheimer's disease)
- Blood pressure monitoring (given cardiovascular disease prevalence in elderly)
- Fall risk assessment at each visit
- Caregiver education regarding medication administration and monitoring for confusion or cognitive decline
Common Pitfalls to Avoid
- Do not assume all ARPIs have equivalent safety profiles - the evidence clearly demonstrates drug-specific differences in cognitive and cardiovascular toxicity
- Do not overlook the twice-daily dosing of darolutamide - ensure patient/caregiver can manage this schedule
- Do not neglect the food requirement - darolutamide bioavailability increases 2.0-2.5-fold with food 9
The convergent evidence from direct comparison trials 1, meta-analyses 7, 4, 5, and guideline recommendations 2, 3 establishes darolutamide as the optimal choice for patients with cognitive impairment and cardiovascular risk factors requiring ARPI therapy.